CERo Therapeutics Holdings, Inc. (CERO)
After hours:
| Previous Close | 1.4000 |
| Open | 1.4200 |
| Bid | 1.3600 x 100 |
| Ask | 1.4300 x 100 |
| Day's Range | 1.3700 - 1.4700 |
| 52 Week Range | 1.3300 - 12.8000 |
| Volume | |
| Avg. Volume | 1,128,873 |
| Market Cap | 20.319M |
| Beta (5Y Monthly) | -0.36 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
GlobeNewswireCERo Therapeutics, Inc. Presents Encouraging Preclinical Data for AML on CER-1236 at Stanford Drug Discovery Symposium Highlighting Tumor Elimination and Manufacturing Attributes
SOUTH SAN FRANCISCO, Calif., April 30, 2024 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc., (NASDAQ:CERO) (“CERo”) an innovative immunotherapy company seeking to advance the next generation of engineered T cell therapeutics that employ phagocytic and innate immune system mechanisms, announces it is presenting preclinical data on its lead product candidate CER-1236 at the Stanford Drug Discovery Symposium, which is being held April 29-30, 2024 in Palo Alto, Calif. The poster, titled, “TIM-4
- Business Wire
CERo Therapeutics, Inc. Announces Publication of Preclinical Research Supporting the Use of Its Clinical Candidate CER-1236 to Treat AML Patients
SOUTH SAN FRANCISCO, Calif., March 07, 2024--CERo Therapeutics Holdings, Inc., (NASDAQ:CERO) ("CERo") an innovative immunotherapy company seeking to advance the next generation of engineered T cell therapeutics that employ phagocytic mechanisms today announced the publication in Clinical Cancer Research, a journal of the American Association for Cancer Research, a paper titled "Therapeutic Targeting of TIM-4-L With Engineered T Cells for Acute Myeloid Leukemia." The paper details preclinical stu
- Business Wire
Phoenix Biotech Acquisition Corp. and CERo Therapeutics, Inc. Announce Close of Business Combination
OAKLAND, Calif. & SOUTH SAN FRANCISCO, Calif., February 14, 2024--Phoenix Biotech Acquisition Corp. (NASDAQ:PBAX) ("PBAX") and CERo Therapeutics, Inc., an innovative immunotherapy company seeking to advance the next generation of engineered T cell therapeutics that employ phagocytic mechanisms ("CERo") today announced that their previously announced business combination has closed, resulting in CERo becoming a publicly-traded company. In connection with the consummation of the business combinati
